SEOM-GEM clinical guidelines for cutaneous melanoma (2023)
Authors:
- Iván Márquez-RodasIMIván Márquez-Rodas
- Eva Muñoz CouseloECEva Muñoz Couselo
- Juan F. Rodríguez MorenoJMJuan F. Rodríguez Moreno
- Ana Mª Arance FernándezAFAna Mª Arance Fernández
- Miguel Ángel Berciano GuerreroMGMiguel Ángel Berciano Guerrero
- Begoña Campos BaleaBBBegoña Campos Balea
- Luis de la Cruz MerinoLMLuis de la Cruz Merino
- Enrique Espinosa ArranzEAEnrique Espinosa Arranz
- Almudena García CastañoACAlmudena García Castaño
- Alfonso Berrocal JaimeAJAlfonso Berrocal Jaime
Open Access
- 15 May 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (11) , 2841-2855
Abstract
Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with locoregional advanced melanoma that can be treated with complete resection, adjuvant—and more recently neoadjuvant—with targeted therapy—BRAF and MEK inhibitors—and immunotherapy—anti-PD-1-based therapies—offer opportunities to reduce the risk of relapse and distant metastases. For patients with advanced disease not amenable to radical treatment, these treatments offer an unprecedented increase in overall survival. A group of medical oncologists from the Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines, based on a thorough review of the best evidence available. The following guidelines try to cover all the aspects from the diagnosis—clinical, pathological, and molecular—staging, risk stratification, adjuvant therapy, advanced disease therapy, and survivor follow-up, including special situations, such as brain metastases, refractory disease, and treatment sequencing. We aim help clinicians in the decision-making process.Keywords
This publication has 62 references indexed in Scilit:
- Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of RegistriesAmerican Journal of Clinical Dermatology, 2023
- Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensusClinical and Translational Oncology, 2022
- 1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trialAnnals of Oncology, 2021
- Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapiesEuropean Journal of Cancer, 2021
- Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumorAnnals of Oncology, 2021
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019European Journal of Cancer, 2020
- KIT as an Oncogenic Driver in Melanoma: An Update on Clinical DevelopmentAmerican Journal of Clinical Dermatology, 2019
- Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studyEuropean Journal of Cancer, 2018
- Epidemiology of cutaneous melanoma in Sweden—Stage‐specific survival and rate of recurrenceInternational Journal of Cancer, 2016
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialThe Lancet, 2015